Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055263 · ClinicalTrials.gov registry record · Phase 1
A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Novacea.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00055263 is a Phase 1 study that has completed, run by Novacea. The registered enrollment target is 60 participants.
The verdict
NCT00055263, a Phase 1 study, has completed, sponsored by Novacea.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purposes of this study are to: * Test the safety of DN-101 in patients with advanced malignancies * Understand how fast the body absorbs, processes, and eliminates DN-101 * Determine the highest dose of DN-101 that is well tolerated by cancer patients * Learn how fast the body absorbs, processes, and eliminates DN-101 compared to the approved product
Interventions
- DRUG DN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055263
The ClinicalTrials.gov registry entry for NCT00055263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novacea, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DN-101 is the first listed.
NCT00055263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055263 about?
NCT00055263 is a clinical study titled "A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies". The purposes of this study are to: * Test the safety of DN-101 in patients with advanced malignancies * Understand how fast the body absorbs, processes, and eliminates DN-101 * Determine the highest dose of DN-101 that is well tolerated by cancer patients * Learn how fast the body absorbs, processe...
What is the current status of trial NCT00055263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2002-03.
What interventions are being tested in trial NCT00055263?
The interventions under investigation include: DN-101 (DRUG).
Who is sponsoring clinical trial NCT00055263?
This trial is sponsored by Novacea, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.